Diagnosis

Vizient Explores Cardiac Ablation Modalities, Advancements in Remote Patient Monitoring and Imaging Alternatives for Early Breast Cancer Detection

Retrieved on: 
Wednesday, December 6, 2023

Vizient, Inc. released its latest Medical Device Tech Watch, exploring cardiac ablation modalities and advancements in remote patient monitoring.

Key Points: 
  • Vizient, Inc. released its latest Medical Device Tech Watch, exploring cardiac ablation modalities and advancements in remote patient monitoring.
  • In addition, this edition reviews new regulations and imaging alternatives for early breast cancer detection.
  • “New technology offers advancements in diagnosis and treatment in patient care and can be accompanied by new regulations as well,” said Josh Aaker, senior director, intelligence, Vizient.
  • Cardiovascular technology advancements: a look at new wearable remote patient monitoring devices and artificial intelligence-enabled care pathways—Technological advancements in cardiovascular health are evolving at a rapid rate.

New Data by Breast Cancer Canada Reveals Almost 3 in 4 Canadians (73%) Turn to Search Engines to Understand a Diagnosis from Their Doctor

Retrieved on: 
Wednesday, December 6, 2023

After receiving a diagnosis from their doctor, almost 3 in 4 Canadians (73%) would turn to a search engine to further understand their diagnosis and options for treatment.

Key Points: 
  • After receiving a diagnosis from their doctor, almost 3 in 4 Canadians (73%) would turn to a search engine to further understand their diagnosis and options for treatment.
  • “Canadians often turn to search engines to gather information about their breast cancer diagnosis.
  • Charlene Newland was advised not to turn to the internet for answers after her Stage 2 breast cancer diagnosis at 33 years old.
  • ** New Data by Breast Cancer Canada Reveals Almost 3 in 4 Canadians (73%) Turn to Search Engines to Understand a Diagnosis from Their Doctor.

Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection

Retrieved on: 
Tuesday, December 5, 2023

Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
  • Known as a “silent killer,” approximately 80% of pancreatic cancer patients discover the disease in late stages when it has already spread and cannot be surgically removed.
  • “Currently, there is no standard early detection test for pancreatic cancer, resulting in an unmet need for innovative solutions to help solve this challenging disease,” said Harmeet Dhani, MD, MSc, Medical Director at Biological Dynamics and Principal Study Investigator.
  • “Collaborating with these cutting-edge institutions expands our work with some of the top cancer researchers in the world.

Veteran Brings Lawsuit Against U.S. Government and Cerner After Defective Veterans Affairs Electronic Health Record (EHR) System Irreparably Delays Cancer Diagnosis, According to Luvera Law Firm

Retrieved on: 
Tuesday, December 5, 2023

In that time, say Bourg’s doctors, the cancer spread to other parts of his body and is now terminal.

Key Points: 
  • In that time, say Bourg’s doctors, the cancer spread to other parts of his body and is now terminal.
  • “What happened to Charlie is not only tragic – it’s inexcusable,” said Mark Kamitomo of Luvera Law Firm, one of the attorneys representing Bourg.
  • “Electronic health records are intended to make care efficient and accurate, passing information seamlessly between providers to give the best care.
  • In this case, Charlie would have been better served if his doctor had sent the referral by handwritten letter.

Celiac Disease Foundation, Celiac Cruise Announce Partnership to Enrich, Expand Travel Experiences for Celiac Disease Community

Retrieved on: 
Tuesday, December 5, 2023

The Celiac Disease Foundation, a leading global patient advocacy organization committed to accelerating diagnosis, treatments, and a cure for celiac disease, and Celiac Cruise, a pioneer in gluten-free travel, today are pleased to announce an innovative partnership to offer safe and delicious gluten-free travel experiences, provide educational opportunities, and foster philanthropy within the celiac disease community.

Key Points: 
  • The Celiac Disease Foundation, a leading global patient advocacy organization committed to accelerating diagnosis, treatments, and a cure for celiac disease, and Celiac Cruise, a pioneer in gluten-free travel, today are pleased to announce an innovative partnership to offer safe and delicious gluten-free travel experiences, provide educational opportunities, and foster philanthropy within the celiac disease community.
  • View the full release here: https://www.businesswire.com/news/home/20231205500367/en/
    “This partnership marks a significant milestone on the path to creating a world where individuals with celiac disease can travel with confidence and enjoy enriching experiences without compromising their health,” said Marilyn G. Geller, CEO of the Celiac Disease Foundation.
  • “By combining the expertise of the Celiac Disease Foundation with the dedication of Celiac Cruise, we are proud to set the premier standard for gluten-free travel.”
    “Celiac Cruise is honored to join forces with the Celiac Disease Foundation to redefine gluten-free travel,” said Maureen Basye, founder of Celiac Cruise.
  • Today, Celiac Cruise and the Celiac Disease Foundation have formalized their partnership, which will offer an array of benefits for the celiac disease community:
    Safe Travel Experiences: All cruise experiences will be tailored to meet the dietary needs of individuals with celiac disease, including dedicated gluten-free menus, strict food handling protocols, and collaboration with both Royal Caribbean and AmaWaterways to create safe, enjoyable environments.

Aquyre Biosciences Announces Appointment of Gregory Bowles as President and CEO

Retrieved on: 
Tuesday, December 5, 2023

Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors.

Key Points: 
  • Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors.
  • At Intuitive Surgical during its early years, he was the Capital Sales Manager where he sold the daVinci Robot in Michigan.
  • Greg’s first startup was EndoGastric Solutions where he held positions as Regional Manager and later as Vice President of Sales.
  • While at Aquyre Biosciences, Greg was the Senior Vice President of Sales and Marketing and has been instrumental in building the company’s commercialization efforts.

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Retrieved on: 
Monday, December 4, 2023

The collaboration encompasses the development of OncoFAP, a proprietary, small organic ligand with ultra-high affinity to Fibroblast Activation Protein (FAP), for applications in the diagnostic imaging of solid tumors.

Key Points: 
  • The collaboration encompasses the development of OncoFAP, a proprietary, small organic ligand with ultra-high affinity to Fibroblast Activation Protein (FAP), for applications in the diagnostic imaging of solid tumors.
  • Under the agreement, the Philogen Group is conducting a Phase 1 clinical study to evaluate the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) in patients with solid tumors.
  • The agreement provides Blue Earth Diagnostics rights to develop and commercialize 68Ga-OncoFAP worldwide.
  • The first three enrolled patients in the trial were imaged in November 2023 at the National Cancer Institute of Milan (INT).

Integrative Life Network and Integrative Health Centers Merge to Redefine the Patient Journey for Mental and Behavioral Health

Retrieved on: 
Thursday, November 30, 2023

Integrative Life Network, LLC (ILN) and Integrative Health Centers, Inc. (IHC) announced today that they have merged to create a new, unified mental and behavioral healthcare company called Peregrine Health, Inc. (Peregrine).

Key Points: 
  • Integrative Life Network, LLC (ILN) and Integrative Health Centers, Inc. (IHC) announced today that they have merged to create a new, unified mental and behavioral healthcare company called Peregrine Health, Inc. (Peregrine).
  • View the full release here: https://www.businesswire.com/news/home/20231130898505/en/
    ILN is a network of residential, partial-hospitalization, and intensive outpatient programs in four states providing high-acuity treatment options for a range of mental and behavioral health disorders.
  • IHC is a nationwide telemedicine platform that connects clinics, hospitals, and health systems in underserved communities with specialized mental and behavioral health providers.
  • “Very few providers have successfully integrated the diagnosis, innovative treatment, and ongoing care of mental and behavioral health disorders into their delivery models.

Naveris Receives Medicare Coverage for NavDx® Test

Retrieved on: 
Thursday, November 30, 2023

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular Diagnostics Services program (MolDX®), established Medicare coverage for NavDx®, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular Diagnostics Services program (MolDX®), established Medicare coverage for NavDx®, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA.
  • NavDx is the first and only clinically validated circulating TTMV-HPV DNA blood test.
  • “This decision underscores the powerful clinical utility of Naveris’ TTMV platform and comes at a time of significant company momentum,” said James McNally, Chief Executive Officer of Naveris.
  • “Medicare coverage and future reimbursement will increase patient access to NavDx and we look forward to continued access expansion through commercial channels in the near future.”

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Retrieved on: 
Thursday, November 30, 2023

HGBL represents a rare and aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with no established standard of care treatment approach.

Key Points: 
  • HGBL represents a rare and aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with no established standard of care treatment approach.
  • For those with relapsed or refractory (R/R) disease, the survival prognosis is 8.6 to 16 months (Laude et al., 2021) .
  • "Receiving Orphan Drug Designation is an important milestone for our latest drug candidate, LP-284, and further validates our data-driven approach to oncology drug discovery and development,” stated Panna Sharma, President & CEO of Lantern Pharma.
  • “This marks the second Orphan Drug Designation (ODD) granted by the FDA for LP-284.